Analytics

Children's Health Alliance senior director of population health Julie Harris discusses how real-time performance metrics can give providers more information at the point of care and reduce their burdens.  

Dr. Benoit Desjardins, University of Pennsylvania radiology professor, explains that, because generative AI models employ "shallow thinking," they can't yet explain how they reach conclusions or replicate the way a human doctor thinks.

Hal Wolf, HIMSS president and CEO, discusses the possible influence that conversations at HIMSS24 between international healthcare leaders could have on healthcare technology policy development in the EU and other regions.

Threat actors are increasingly using AI to generate hacking attempts and phishing scams. Jeff Webber, Intelliguard CTO, calls for cybersecurity vendors to create AI-powered solutions to fight these new threats.

Jerry Shultz, Lightbeam Health Solutions' president, says the company's AI identifies COPD patients who need personalized interventions, reducing readmissions and realizing millions of dollars in savings for clients.

Before deciding how and when to adopt AI, Nicolas Ostrowski of Future Processing advises businesses to have a technology roadmap, sound data practices and strong cybersecurity in place.

Amid the trend of healthcare companies leveraging AI, Jerry Villacres, Manifold's VP of Sales, Cloud Solutions, cautions that they must first implement a sound data strategy to make the most out of those tools.

Mark Polyak, president of global data management at IPSOS, says LLMs can "talk" to patients about administrative tasks like scheduling, but bias and model compatibility must be addressed before clinical deployments.  

Harvard research associate Brian Spisak discusses how a "leadership-first, tech-last" approach can prevent organisations from deploying ticking time bombs.  

Michael Pace, founder and president of PalmHealthCo, highlights how his company advises organizations, including pharma, in commercialization and go-to-market strategies for digital therapeutics - and his experience at Pear Therapeutics.